Literature DB >> 7991039

Glucose-induced insulin secretion in uremia: role of 1 alpha,25(HO)2-vitamin D3.

V Allegra1, G Luisetto, G Mengozzi, L Martimbianco, A Vasile.   

Abstract

To evaluate the role and mechanism of action of calcitriol on glucose-induced insulin secretion in uremia, 17 patients with severe chronic renal failure were studied. Glucose metabolism was investigated by the intravenous glucose tolerance test (IVGTT) before and after treatment for 21 days with 0.5 microgram/day of calcitriol and 500 mg/day of calcium (C+Ca) (6 cases) or 0.5 microgram/day of calcitriol alone (C) (11 cases). After these evaluations the patients on C+Ca were shifted to C and 6 patients on C were shifted to C+Ca, and IVGTT was repeated 21 days after the shift. For each test plasma glucose (G), immunoreactive insulin (IRI) and C-peptide (C-p) were measured at -30, 0, 2, 5, 15, 30, 45, 60 min, and baseline plasma values of 1 alpha,25(HO)2-vitamin D3, C-terminal parathyroid hormone (PTH-C), intact parathyroid hormone (PTH-I), calcitonin, and serum values of total and ionized calcium were dosed. Also, glucose constant decay (K-G), insulin response (IRI area), C-p production (C-p area), insulinogenic index (IGI) and insulin resistance index (RI) were calculated. A historical group of 21 healthy volunteers formed the normal controls. 1 alpha,25(HO)2-vitamin D3 plasma levels in uremic patients before treatment were significantly lower than normal range. As compared to controls, uremic patients showed significantly lower K-G, IRI area and IGI values and significantly higher RI values. After treatment with C or C+Ca, the insulin response improved significantly at 2 and 5 min and G decrement was more marked at 30, 45 and 60 min.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7991039     DOI: 10.1159/000188085

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  9 in total

Review 1.  Measurement of insulin resistance in chronic kidney disease.

Authors:  Hien Pham; Kristina M Utzschneider; Ian H de Boer
Journal:  Curr Opin Nephrol Hypertens       Date:  2011-11       Impact factor: 2.894

2.  The effect of different doses of vitamin D(3) on markers of vascular health in patients with type 2 diabetes: a randomised controlled trial.

Authors:  M D Witham; F J Dove; M Dryburgh; J A Sugden; A D Morris; A D Struthers
Journal:  Diabetologia       Date:  2010-07-02       Impact factor: 10.122

Review 3.  Vitamin D and diabetes.

Authors:  C Mathieu; C Gysemans; A Giulietti; R Bouillon
Journal:  Diabetologia       Date:  2005-06-22       Impact factor: 10.122

Review 4.  Vitamin D and human health: lessons from vitamin D receptor null mice.

Authors:  Roger Bouillon; Geert Carmeliet; Lieve Verlinden; Evelyne van Etten; Annemieke Verstuyf; Hilary F Luderer; Liesbet Lieben; Chantal Mathieu; Marie Demay
Journal:  Endocr Rev       Date:  2008-08-11       Impact factor: 19.871

Review 5.  Vitamin D and glucose metabolism in chronic kidney disease.

Authors:  Ian H de Boer
Journal:  Curr Opin Nephrol Hypertens       Date:  2008-11       Impact factor: 2.894

6.  A pilot study of active vitamin D administration and insulin resistance in African American patients undergoing chronic hemodialysis.

Authors:  Adriana M Hung; Mary B Sundell; Natalia E Plotnikova; Aihua Bian; Ayumi Shintani; Charles D Ellis; Edward D Siew; T Alp Ikizler
Journal:  J Ren Nutr       Date:  2012-09-07       Impact factor: 3.655

7.  Efficacy of vitamin D3-fortified-yogurt drink on anthropometric, metabolic, inflammatory and oxidative stress biomarkers according to vitamin D receptor gene polymorphisms in type 2 diabetic patients: a study protocol for a randomized controlled clinical trial.

Authors:  Sakineh Shab-Bidar; Tirang R Neyestani; Abolghassem Djazayery
Journal:  BMC Endocr Disord       Date:  2011-06-22       Impact factor: 2.763

8.  The role of 25-hydroxyvitamin D deficiency in promoting insulin resistance and inflammation in patients with chronic kidney disease: a randomised controlled trial.

Authors:  William G Petchey; Ingrid J Hickman; Emma Duncan; Johannes B Prins; Carmel M Hawley; David W Johnson; Katherine Barraclough; Nicole M Isbel
Journal:  BMC Nephrol       Date:  2009-12-10       Impact factor: 2.388

9.  Paricalcitol does not improve glucose metabolism in patients with stage 3-4 chronic kidney disease.

Authors:  Ian H de Boer; Michael Sachs; Andrew N Hoofnagle; Kristina M Utzschneider; Steven E Kahn; Bryan Kestenbaum; Jonathan Himmelfarb
Journal:  Kidney Int       Date:  2012-08-22       Impact factor: 10.612

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.